Last updated: February 15, 2026
Product Overview
NDC 25021-0464 is a formulated drug identified as Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). It is a fixed-dose combination used for treating HIV-1 infections. The drug gained approval from the FDA in February 2018 and is marketed as a once-daily oral regimen.
Market Size and Penetration
The HIV treatment market has maintained steady growth driven by expanding patient access and updated treatment guidelines.
- Global HIV market size (2022): Estimated at approximately $20 billion, with North America accounting for roughly 45%.
- Market share of Biktarvy (2022): Estimated at 60% among first-line HIV therapies, with peak sales exceeding $7 billion annually.
- Patient population: Approximately 38 million people living with HIV worldwide as of 2022, with the U.S. representing about 1.2 million cases.
Competitive Landscape
Biktarvy faces competition from other combination drugs:
- Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide).
- Gilead's Dolutegravir-based regimens: Tivicay (dolutegravir) combinations.
- ViiV's Cabotegravir (long-acting injectable).
- Generic formulations: Limited but emerging as patent protections expire.
Patent and Regulatory Considerations
Gilead holds patents protecting Biktarvy until at least 2030, with some patents possibly extending to 2035 due to supplementary protections.
- Patent challenges: Patent litigations filed by generic manufacturers such as Teva and Mylan aim for patent extensions or approvals for generics.
Price Projections
Pricing varies by geography, payer status, and patent/differentiation strategies:
| Region |
Estimated Wholesale Price (per 30-day supply) |
Price Trends (2023-2028) |
| U.S. |
Approximately $3,200 |
Stable with slight increases (~3% annually) due to inflation and evolving payer negotiations. |
| Europe |
Range €2,800–€3,300 (~$3,100–$3,600) |
Stable, with regional pricing negotiations and biosimilar entry in some countries. |
| Rest of World |
$2,000–$2,800 |
Lower due to weaker purchasing power and negotiated national prices. |
Future Price Trends
- Price reductions are expected as patent exclusivity diminishes and generics enter the market.
- Cost reductions in the U.S. may accelerate under pressure from Medicaid and HIV advocacy groups, potentially bringing prices down to $2,500–$2,800 per month by 2028.
- In Europe, biosimilar competition might lead to price erosion of 10-15% over five years.
Market Access and Reimbursement
Insurance coverage in the U.S. and international health systems influences pricing. Gilead’s agreements with insurers and pharmacy benefit managers (PBMs) aim to maintain high margins. Expiry of key patents could lead to increased access and lower prices but threaten current revenue streams.
Implications for Stakeholders
- Pharmaceutical companies: Sensitive to patent litigation outcomes and biosimilar entry.
- Investors: Must monitor patent status, market penetration, and medical guideline updates.
- Healthcare providers: Driven by formulary preferences, which influence drug substitution and cost management.
Conclusion
NDC 25021-0464 (Biktarvy) holds a dominant market position in HIV treatment actively generating over $7 billion annually. Its future revenues depend on patent stability, competitive entry, and evolving treatment protocols, with prices likely to decline gradually as biosimilars and generics penetrate the market.
Key Takeaways
- Biktarvy commands a high retail price (~$3,200/month in the U.S.) driven by its market share and patent protection.
- The HIV treatment market is growing, with Biktarvy maintaining a leading position through 2023–2028.
- Patent expiration and biosimilar/pre-grant challenges could reduce prices by double digits within five years.
- International prices vary widely, influenced by regional policies and market size.
- Ongoing patent litigations and market dynamics will shape future revenue streams and pricing strategies.
FAQs
1. When are the patents for Biktarvy expected to expire?
Patents are currently protected until at least 2030, with some extensions possible until 2035 depending on legal challenges and supplementary protections.[1]
2. How likely are biosimilars or generics to enter the market?
The entry of biosimilars or generics is expected after patent expiration, but the process may be delayed by patent litigations and regulatory hurdles.[2]
3. What is the impact of patent challenges on Biktarvy's market?
Legal challenges by generic competitors could lead to patent invalidation or extensions, influencing market exclusivity and pricing.[3]
4. Are there regional differences in pricing strategies?
Yes, U.S. prices tend to be higher due to market dynamics and patent protections, whereas European and emerging markets negotiate lower prices through government policies.[4]
5. What are the key drivers for Biktarvy’s future sales?
Market penetration in new treatment-naïve patients, extension of patent protections, and the adoption rate by clinicians are critical factors.[5]
Sources
[1] FDA Flash: Patent information for Biktarvy.
[2] Gilead patent portfolio details, 2023.
[3] Legal analyses of Biktarvy patent litigations.
[4] Global HIV market pricing reports, 2022.
[5] Treatment guidelines and market adoption studies, 2023.
